LONDON, Sept 22 (Reuters) - Irish drugmaker Elan Corp Plc and U.S. partner Biogen Idec Inc said on Monday their Tysabri drug not only slows the progress of multiple sclerosis but, unlike other treatments, also leads to improvements in the condition of patients after two years.
